Scope
NICE guideline NG145 covers the assessment and management of thyroid disease in adults (16 and over), children and young people. It includes a 2023-dated recommendation on biotin interference. It covers who to test and which thyroid function tests to use. It addresses levothyroxine treatment and monitoring for primary and subclinical hypothyroidism. For thyrotoxicosis, it covers causal diagnosis and choosing between antithyroid drugs, radioactive iodine and surgery for Graves' disease and toxic nodular goitre. It also covers antithyroid drug safety, biochemical follow-up, subclinical hyperthyroidism, and investigation and management of goitre or nodules with normal thyroid function. Many recommendations are framed as 'consider'.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Who to test and which tests to use
- Offer thyroid function testing to adults, children and young people with type 1 diabetes or another autoimmune disease, or with new-onset atrial fibrillation. [1]
- Consider testing when thyroid disease is clinically suspected, remembering that one symptom alone may not indicate it. Also consider testing in depression or unexplained anxiety, and in children and young people with abnormal growth or unexplained changes in behaviour or school performance. Thyroid symptoms in menopausal women may be mistaken for menopause. [1]
- Avoid testing during an acute illness, because results may be affected, unless thyroid dysfunction is suspected as the cause. Do not test solely because a person has type 2 diabetes. [1]
- For adults without suspected pituitary disease, consider TSH alone. Add FT4 on the same sample if TSH is high, or FT4 and FT3 if TSH is low. For adults with suspected secondary (pituitary) dysfunction, and for children and young people, consider TSH plus FT4, adding FT3 on the same sample if TSH is low. [1]
- Ask people with suspected thyroid dysfunction about biotin intake, because high-dose biotin supplements can falsely raise or lower test results. [1]
Primary hypothyroidism
- Levothyroxine is first-line treatment at all ages. Liothyronine, alone or combined with levothyroxine, should not be routinely offered: evidence of benefit over levothyroxine monotherapy is insufficient and long-term harms are uncertain. Natural thyroid extract should not be offered. [1]
- For adults under 65 without cardiovascular disease, consider a starting dose of 1.6 micrograms per kilogram per day, rounded to the nearest 25 micrograms. For adults aged 65 and over or with cardiovascular disease, consider starting at 25 to 50 micrograms daily, then titrating. [1]
- Aim to keep TSH within the reference range. If symptoms persist, further dose adjustment may be considered, but avoid TSH suppression or thyrotoxicosis. TSH may take up to 6 months to normalise after a very high baseline or prolonged untreated disease. In adults, consider TSH every 3 months until stable (2 similar in-range values 3 months apart), then annually. [1]
Subclinical hypothyroidism in adults
- When deciding on treatment, weigh features of underlying thyroid disease: hypothyroid symptoms, prior radioactive iodine or thyroid surgery, or raised autoantibodies. Consider levothyroxine when TSH is 10 mlU/litre or higher on 2 occasions 3 months apart. [1]
- For symptomatic adults under 65 whose TSH is above range but below 10 mlU/litre on 2 occasions 3 months apart, consider a 6-month levothyroxine trial. If symptoms do not improve, recheck TSH and adjust the dose if it is still raised. If symptoms persist with TSH in range, consider stopping. [1]
- For untreated adults, or those who have stopped levothyroxine, consider TSH and FT4 yearly if features suggest underlying thyroid disease, otherwise every 2 to 3 years. [1]
Thyrotoxicosis and hyperthyroidism: diagnosis and treatment
- In adults, distinguish hyperthyroidism from thyrotoxicosis without hyperthyroidism by measuring TRAbs to confirm Graves' disease, and consider technetium scanning if TRAbs are negative. Ultrasound should only be considered if a thyroid nodule is palpable. [1]
- In children and young people, make the same distinction by measuring TPOAbs and TRAbs, and consider technetium scanning if TRAbs are negative. [1]
- Transient thyrotoxicosis without hyperthyroidism usually needs only supportive care, such as beta-blockers. In primary care, antithyroid drugs plus supportive care may be considered for adults with hyperthyroidism awaiting specialist assessment. Antithyroid drugs should be offered to control hyperthyroidism while people await radioactive iodine or surgery. [1]
- For adults with Graves' disease, radioactive iodine is the default first-line definitive treatment. Exceptions are when antithyroid drugs are likely to achieve remission, or when radioactive iodine is unsuitable (for example, compression concerns, suspected malignancy, pregnancy or plans to conceive or father a child within 4 to 6 months, or active thyroid eye disease). [1]
- Where remission with antithyroid drugs is likely, for example in mild uncomplicated Graves' disease, offer a choice between a 12- to 18-month drug course and radioactive iodine. Offer the drug course alone if both radioactive iodine and surgery are unsuitable. For persistent or relapsed disease after drugs, consider radioactive iodine or surgery. [1]
- Total thyroidectomy is the first-line definitive option for adults with Graves' disease when there are compression concerns, suspected malignancy, or both radioactive iodine and antithyroid drugs are unsuitable. [1]
- For adults with hyperthyroidism from multiple nodules, radioactive iodine is first-line unless unsuitable; if so, offer total thyroidectomy or life-long antithyroid drugs. For a single toxic nodule, offer radioactive iodine (if suitable) or hemithyroidectomy, with life-long antithyroid drugs if neither is suitable. [1]
- Children and young people with Graves' disease should be offered antithyroid drugs for at least 2 years, possibly longer. Use titrated carbimazole and review the need for treatment every 2 years. Carbimazole use is subject to MHRA advice on contraception and acute pancreatitis risk, and is off label under 2 years. After relapse, consider continuing or restarting drugs, or discuss radioactive iodine or total thyroidectomy. [1]
- For adults with Graves' disease receiving definitive drug therapy, offer carbimazole for 12 to 18 months, by block-and-replace or titration, then review. Carbimazole use is subject to MHRA advice on contraception and acute pancreatitis. Consider propylthiouracil after carbimazole adverse reactions, in pregnancy or planned pregnancy within 6 months, or with prior pancreatitis. [1]
- Check full blood count and liver function before starting antithyroid drugs. Do not monitor them routinely unless agranulocytosis or liver dysfunction is suspected. If agranulocytosis occurs, stop all antithyroid drugs permanently and consider specialist referral. [1]
Follow-up of hyperthyroidism and subclinical hyperthyroidism
- After radioactive iodine, consider TSH, FT4 and FT3 every 6 weeks for the first 6 months until TSH normalises. Consider antithyroid drugs until the 6-month review if hyperthyroidism persists, and offer levothyroxine if hypothyroidism develops off antithyroid drugs. On antithyroid drugs, consider TSH, FT4 and FT3 every 6 weeks until TSH normalises, then cascaded TSH every 3 months. [1]
- Consider specialist advice for adults with subclinical hyperthyroidism who have 2 TSH readings below 0.1 Miu/litre at least 3 months apart, plus evidence of thyroid disease or thyrotoxic symptoms. Consider specialist advice for all children and young people with subclinical hyperthyroidism. For untreated adults, consider TSH every 6 months. [1]
Thyroid enlargement with normal thyroid function
- Offer ultrasound for palpable thyroid enlargement or focal nodularity when malignancy is suspected. Decide on fine needle aspiration cytology using an established ultrasound grading system, and perform the aspiration under ultrasound guidance. [1]
- Do not treat adults with benign enlargement, normal thyroid function and mild or no symptoms, unless there is breathing difficulty or clinical concern such as marked airway narrowing. For a compressive cyst or predominantly cystic nodule with no vascular components, offer aspiration, with possible ethanol ablation if fluid re-accumulates. For a non-cystic nodule or multinodular or diffuse goitre causing compressive symptoms, consider surgery (especially with marked airway narrowing) or radioactive iodine ablation if uptake is demonstrable. [1]
Limitations and use
- Only the clinical recommendations chapter was available; research recommendations, rationale and impact, and update-history chapters were not reviewed.
- Flowcharts and visual algorithms were represented only by alternative text.
- The guideline refers out to other NICE guidance for suspected thyroid and head and neck cancer referral, coeliac disease testing in autoimmune thyroid disease, and shared decision making; these are not covered here.
- This summary condenses several detailed recommendations, including: paediatric levothyroxine monitoring schedules; subclinical hypothyroidism thresholds and monitoring in children (including those aged 28 days to 2 years); monitoring after surgery and after stopping antithyroid drugs; and percutaneous thermal ablation.
- Definitions used: adults are people aged 16 and over, and children and young people are under 16.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Thyroid disease: assessment and management
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 20 November 2019
- Publisher’s latest update
- 12 October 2023
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.